Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLRMT | O00411 | 1/20 | 0.38 |
| ▸ | P2RY2 | P41231 | 10/20 | 0.37 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.37 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.36 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.36 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.36 |
| ▸ | POLA1 | P09884 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17124608 | 0.92 | POLRMT (0.38) | POLRMTP2RY2P2RY4P2RX1P2RX3 | |
| SCHEMBL12393421 | 0.92 | P2RY2 (0.39) | POLRMTP2RY2P2RY4P2RX1P2RX3 | |
| SCHEMBL10148632 | 0.92 | TMPRSS2 (0.34) | — | |
| Gs-441326 SCHEMBL10149536 | 0.91 | POLRMT (0.47) | POLRMTP2RX1P2RX3P2RX4 | |
| SCHEMBL12397122 | 0.89 | P2RX3 (0.36) | POLRMTP2RY2P2RY4P2RX1P2RX3 | |
| SCHEMBL12464640 | 0.84 | POLRMT (0.45) | POLRMTP2RX1P2RX3P2RX4 | |
| SCHEMBL10142499 | 0.83 | POLRMT (0.47) | POLRMTP2RY2P2RY4P2RX1P2RX3 | |
| SCHEMBL17129823 | 0.83 | POLRMT (0.47) | POLRMTP2RX1P2RX3P2RX4 | |
| SCHEMBL17129838 | 0.83 | POLRMT (0.47) | POLRMTP2RX1P2RX3P2RX4 | |
| SCHEMBL12393465 | 0.83 | TMPRSS2 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8455451-B2 | 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2013-06-04 | — | — | US | disclosed |
| US-20120009147-A1 | 2'-FLUORO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2012-01-12 | — | — | US | disclosed |
| US-20110070194-A1 | 2'-FLUORO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2011-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120009147-A1 | 2'-FLUORO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | PNP, NSUN2, CDA | POLRMT 281/4885P2RY2 309/4885P2RY4 206/4885 |
| US-20110070194-A1 | 2'-FLUORO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | PNP, RNGTT, SLC29A1 | POLRMT 188/4885P2RY2 271/4885P2RY4 165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.